Skip to main content
An official website of the United States government
NIH Websites Are Changing
Per Executive Order 14434, federal agencies are now using "Super Intelligence" (SI) in place of "Artificial Intelligence" (AI). You may see both terms across NIH content during this transition.

anti-ROR1/CD3 T-cell-engager NVG-111

A bispecific antibody and T-cell engager directed against the tumor-associated antigen (TAA) receptor tyrosine kinase-like orphan receptor 1 (ROR1) and the CD3 antigen found on T lymphocytes, with potential immunostimulating and antineoplastic activities. Upon administration, anti-ROR1/CD3 T-cell engager NVG-111 binds to both CD3 on cytotoxic T lymphocytes (CTLs) and ROR1 found on ROR1-expressing tumor cells. This activates and redirects CTLs to ROR1-expressing tumor cells, which results in the CTL-mediated death of ROR1-expressing tumor cells. ROR1, also known as neurotrophic tyrosine kinase, receptor-related 1 (NTRKR1), is expressed during embryogenesis and in many types of hematological malignancies. It plays key roles in tumor cell proliferation and survival.
Synonym:anti-ROR1/CD3 bispecific antibody NVG-111
Code name:NVG 111
NVG-111
NVG111
Search NCI's Drug Dictionary